MedPath

The effect of transcranial brain stimulation on patients with schizophrenia

Phase 3
Conditions
The effect of TDCS of on schizophrenia.
Registration Number
IRCT20210406050874N1
Lead Sponsor
Tabriz University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Having a diagnosis of psychiatric illness in Razi Hospital, Tabriz
No disability
Family consent to participate in the program
Having a diagnosis of Schizophrenia (diagnosis of schizophrenia is based on the DSM5 diagnostic criteria and SCID-based psychiatric interview and clinical examination)

Exclusion Criteria

Age under 18 and over 45 years
History of severe sensory-motor disorders
Vision problems
Hearing problems
Severe intelligence and cognitive impairments
Epilepsy and seizures
History of brain mass
Substance dependence
History of intracranial implants (such as prostheses, shunts, stimulators, electrodes)
The presence of any metal object that is close to the head (for example, inside the mouth) and can not be separated
Having a cardiac pacemaker
History of recent strokes and MI
History of degenerative brain disorders such as Alzheimer's and Parkinson's diseases.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum levels of total and Phosphorylated Tau Protein in Patients with Schizophrenia. Timepoint: 2cc of fasting blood sample for each patient is taken once before starting and once after all sessions of TDCS. Method of measurement: By ELISA kits and in the laboratory.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath